Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder characterized by tumor predisposition and a wide spectrum of neurologic manifestations. Among its most serious complications are plexiform neurofibromas (PNs), which can cause significant morbidity…
Desmoid tumors (DTs) are rare, locally invasive neoplasms that present significant challenges due to their variable presentation, diagnostic delays, and the evolving therapeutic landscape. Oncology nurses and nurse practitioners often lack sufficient training in identifying early…
Neurofibromatosis Type 1 (NF1) requires a nuanced clinical approach due to its diverse neuro-oncologic manifestations and potential for significant morbidity. To facilitate timely diagnosis and intervention, health care professionals must recognize early neurologic signs and tumor…
Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians face…
Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians face…
Delayed diagnosis of cervical cancer often leads to poor prognosis and lower survival rates, especially in advanced stages. Recent therapeutic advancements, including immune-checkpoint inhibitors and antibody-drug conjugates (ADCs), offer new hope for managing advanced cervical cancer….
Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of clinical manifestations, both near- and long-term, makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further…
Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of clinical manifestations, both near- and long-term, makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further…
Upper gastrointestinal (GI) cancers are often undetected until late stages, leading to a poor prognosis. Treatment may be delayed or inappropriately assigned due to a lack of robust biomarker testing. To optimize patient outcomes, oncology clinicians…